Media



December 16, 2019

AKERO THERAPEUTICS COMPLETES ENROLLMENT IN PHASE 2A STUDY IN NASH

December 16, 2019 SAN FRANCISCO, Dec. 16, 2019 /PRNewswire/ — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that it has completed enrollment in the Phase 2a BALANCED study of AKR-001, a novel FGF21 analog, for the treatment of NASH. “We believe […]

Read More

November 13, 2019

AKERO THERAPEUTICS TO PRESENT AT THE JEFFERIES 2019 LONDON HEALTHCARE CONFERENCE

November 13, 2019 SAN FRANCISCO, Nov. 13, 2019 /PRNewswire/ — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that members of the management team will provide a business overview and update at the Jefferies 2019 London Healthcare Conference at 8:00 a.m. GMT on Wednesday, November 20, 2019. A […]

Read More

November 12, 2019

AKERO THERAPEUTICS REPORTS RECENT HIGHLIGHTS AND THIRD QUARTER 2019 FINANCIAL RESULTS

November 12, 2019 SAN FRANCISCO, Nov. 12, 2019 /PRNewswire/ — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today reported third quarter 2019 financial results for the period ending September 30, 2019. “The third quarter of 2019 was a period of continued clinical and manufacturing progress […]

Read More

November 11, 2019

Akero Chief Development Officer Kitty Yale Named to 2019 Fierce Pharma “Fiercest Women in Life Sciences”

November 11, 2019 Akero Therapeutics is thrilled to announce that its chief development officer Kitty Yale has been recognized by FiercePharma as one of 2019’s “Fiercest Women in Life Sciences.” Kitty joined Akero from Gilead Sciences, Inc. where she led global clinical operations and management of the company’s oncology, HIV, inflammation and liver disease trials. […]

Read More

October 3, 2019

Akero Therapeutics and InSphero partner to evaluate AKR-001 using InSphero’s 3D InSight™ Human Liver Disease platform

SCHLIEREN, Switzerland and SAN FRANCISCO, Oct. 3, 2019 /PRNewswire/ — Akero Therapeutics and InSphero AG today announced that Akero has selected InSphero’s 3D InSight™ Human Liver Disease Platform to characterize the physiological effects of AKR-001 in different types of liver cells. AKR-001 is designed to be a novel, long-acting FGF21 analog, currently being evaluated in a Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH)

Read More

September 4, 2019

AKERO THERAPEUTICS TO PRESENT AT THE MORGAN STANLEY 17TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

A clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that members of the management team will provide a business overview and update at the Morgan Stanley 17th Annual Global Healthcare Conference at 5:25 p.m. ET on Monday, September 9, 2019 in New York, NY.

Read More

August 12, 2019

AKERO THERAPEUTICS REPORTS RECENT HIGHLIGHTS AND SECOND QUARTER 2019 FINANCIAL RESULTS

— Advanced AKR-001 into Phase 2a BALANCED clinical study in NASH —— Raised $98.4 million in aggregate net proceeds from Initial Public Offering — SAN FRANCISCO, Aug. 12, 2019 /PRNewswire/ — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today provided a business update and […]

Read More

July 2, 2019

Akero Therapeutics Announces Dosing of First Patient in Phase 2a Study of AKR-001 to Treat NASH (BALANCED)

A clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced

Read More



CONTACT US

West coast headquarters

170 Harbor Way
3rd Floor
South San Francisco, CA 94080
650-487-6488

East coast office

400 Technology Square
10th Floor
Cambridge, MA 02139

© 2019 Akero Therapeutics, Inc. All rights reserved. Terms of Use.